On 20 June 2026, the Ministry of Health & Family Welfare prohibited the manufacture, sale and distribution of 16 Fixed Dose Combinations (FDCs) under Section 26A of the Drugs and Cosmetics Act, 1940, with immediate effect and "in public interest." The action followed Supreme Court directions mandating a comprehensive review of irrational FDCs, after which the Drugs Technical Advisory Board (DTAB) examined the combinations and found them to lack therapeutic justification while posing risk to patients. For CDS and OTA aspirants, this is a textbook case study in how India's statutory drug-regulation machinery converts a court order and expert advice into binding regulatory action.
What is a Fixed Dose Combination — and why "irrational" ones are dangerous
A Fixed Dose Combination (FDC) is a single dosage form — usually one tablet, capsule or syrup — that contains two or more active pharmaceutical ingredients in a fixed ratio. Rational FDCs do exist and are valuable: the WHO recommends fixed combinations for tuberculosis and HIV because they simplify dosing and improve patient adherence. The problem is the irrational FDC — a combination that offers no added therapeutic benefit over the individual drugs, or where the ingredients should never be taken together.
Irrational FDCs are dangerous for three connected reasons. First, they expose patients to the side-effects of multiple drugs when only one (or none) is medically needed. Second, many combine an antibiotic with another agent, encouraging the unnecessary, blanket use of antimicrobials — a direct driver of antimicrobial resistance (AMR). Third, they undermine the principle of the "rational use of medicines", which holds that patients should receive medications appropriate to their clinical need, in the right dose, for the right duration, at the lowest cost. The WHO Essential Medicines List, which India's own National List of Essential Medicines mirrors, is built on exactly this logic of need-based, evidence-backed prescribing.
The legal hook: Section 26A and the Drugs and Cosmetics Act, 1940
India's primary drug-control statute is the Drugs and Cosmetics Act, 1940, supplemented by the Drugs and Cosmetics Rules, 1945. The Act regulates the import, manufacture, distribution and sale of drugs and cosmetics to ensure they are safe, effective and of standard quality.
The specific power used in this ban is Section 26A, which empowers the Central Government to prohibit the manufacture, sale or distribution of any drug or cosmetic if it is "satisfied that the use of such drug is likely to involve any risk to human beings or animals, or that it does not have the therapeutic value claimed for it, or contains ingredients not having such value, and that in the public interest it is necessary or expedient so to do." The phrase "in public interest" is the legal anchor of every FDC ban notification, and examiners frequently test which section authorises such prohibitions. Understanding how a statute delegates emergency regulatory power to the executive is also useful background for the broader study of statutory commissions and advisory bodies.
The regulatory architecture: CDSCO, DCGI, DTAB and the states
Drug regulation in India is a shared (concurrent) responsibility between the Centre and the states, and aspirants should be able to name the key institutions:
- Central Drugs Standard Control Organisation (CDSCO) — the national drug regulator under the Ministry of Health, headed by the DCGI. It functions as India's equivalent of the US FDA, handling approval of new drugs and clinical trials, import licensing, and setting national standards.
- Drugs Controller General of India (DCGI) — the head of CDSCO, who approves new drugs and FDCs, licenses certain categories, and lays down uniform standards across the country.
- State Drug Controllers / State Licensing Authorities — they grant manufacturing and sale licences for most drugs and enforce the Act within their states. A long-standing problem with irrational FDCs was that some were licensed by state authorities without central approval.
- Drugs Technical Advisory Board (DTAB) — the highest statutory body advising the Centre and states on technical matters under the Act. It is the DTAB's recommendation that underpins the present ban.
- Drugs Consultative Committee (DCC) — a statutory body that promotes uniformity in the administration of the Act across states.
Both the DTAB and the DCC are creatures of the Drugs and Cosmetics Act itself, which makes them statutory advisory bodies — a distinction examiners love, because they are neither constitutional nor purely executive bodies.
How this ban came about: the Supreme Court, DTAB and the 2018 precedent
The 2026 prohibition did not appear in isolation. It is the latest chapter in a decade-long clean-up of India's FDC market. The story runs through the Kokate Committee, set up to examine hundreds of FDCs that were being sold without proper central evaluation of their safety and efficacy. Acting on its findings, the government in 2018 banned over 300 FDCs — one of the largest such actions anywhere — though the matter was repeatedly litigated, with manufacturers challenging the bans in court.
The Supreme Court ultimately directed a comprehensive, expert-led review of the disputed combinations rather than blanket action without scrutiny. The DTAB (often through sub-committees of experts) then examined each FDC on its therapeutic merits. The 16 FDCs banned on 20 June 2026 are those the Board concluded had no therapeutic justification or posed a clear risk — exactly the twin grounds Section 26A specifies. This sequence — court direction → expert technical review → executive notification under statute — is the model answer for how evidence-based regulation is supposed to work in a democracy.
The bigger picture: antimicrobial resistance and rational medicine use
Many irrational FDCs bundle antibiotics into combinations meant for coughs, colds or pain, encouraging people to consume antibiotics they do not need. This fuels antimicrobial resistance (AMR) — the process by which bacteria, viruses and other microbes evolve to survive the drugs designed to kill them, rendering once-curable infections deadly. AMR is recognised globally as a "silent pandemic," and the WHO, along with India's own National Action Plan on AMR, treats curbing irrational antibiotic use as a frontline defence. Cracking down on irrational FDCs is therefore not just a consumer-safety measure but a public-health and national-security concern, since drug-resistant infections threaten both civilian and military medical readiness. The continuing relevance of these issues makes drug regulation a regular feature of the CDS-OTA current affairs cycle.
🎯 Practice MCQs
Q1. Under which section of the Drugs and Cosmetics Act, 1940 can the Central Government ban a drug "in public interest"? (a) Section 18 (b) Section 26A (c) Section 27 (d) Section 33P → (b) — Section 26A empowers prohibition where a drug poses risk or lacks therapeutic value.
Q2. A "Fixed Dose Combination" is best defined as a medicine that: (a) is dosed once daily (b) contains two or more active ingredients in a fixed ratio in one form (c) is sold without prescription (d) is on the essential medicines list → (b) — An FDC combines two-plus active drugs in fixed proportions in a single dosage form.
Q3. The DCGI is the head of which organisation? (a) ICMR (b) NPPA (c) CDSCO (d) FSSAI → (c) — The Drugs Controller General of India heads the Central Drugs Standard Control Organisation.
Q4. Which body is the highest statutory technical advisory board under the Drugs and Cosmetics Act? (a) Drugs Consultative Committee (b) Drugs Technical Advisory Board (c) Central Drugs Laboratory (d) Pharmacy Council of India → (b) — The DTAB advises the Centre and states on technical matters and recommended the FDC ban.
Q5. Antimicrobial resistance (AMR) primarily refers to: (a) allergy to antibiotics (b) microbes evolving to survive drugs meant to kill them (c) drug expiry (d) resistance of patients to treatment → (b) — AMR is the evolution of pathogens that no longer respond to antimicrobial drugs.
Q6. The 2018 ban of over 300 FDCs was informed by the recommendations of the: (a) Mashelkar Committee (b) Kokate Committee (c) Hathi Committee (d) Katoch Committee → (b) — The Kokate Committee reviewed FDCs sold without proper central evaluation.
Q7. Drug regulation in India is a responsibility shared between the Centre and states because the subject lies in the: (a) Union List (b) State List (c) Concurrent List (d) residuary powers → (c) — Drugs and poisons fall in the Concurrent List, hence shared regulation.
Q8. The "rational use of medicines" principle is most closely reflected in the: (a) WHO Essential Medicines List (b) Companies Act (c) Insolvency Code (d) Disaster Management Act → (a) — The Essential Medicines List embodies need-based, evidence-backed prescribing.
📋 How this gets asked (PYQ pattern)
CDS and OTA papers repeatedly probe which statute and which section authorise a government action, and the Drugs and Cosmetics Act with its Section 26A power is a classic match-the-pair and one-liner target. Equally common is the institution-identification angle — distinguishing CDSCO, DCGI, DTAB and state drug controllers, and classifying the DTAB and DCC as statutory (not constitutional) advisory bodies. Health-and-science General Knowledge sections regularly test antimicrobial resistance, FDCs and the WHO Essential Medicines List as standalone facts. The fresh 2026 hook — a Supreme-Court-driven, DTAB-vetted ban of 16 FDCs — lets examiners frame a current-affairs question that links the judiciary, an expert body and executive notification in a single chain, so know the sequence rather than isolated facts.
Want a daily, exam-ready current-affairs feed like this? Follow our continuously updated CDS-OTA current affairs digests and turn headlines into marks — then join a structured batch through our upcoming Cavalier Delhi courses.
✍️ Written by Aditya Tiwari — Defence current-affairs & GK faculty at The Cavalier. Reviewed by the Cavalier Faculty Desk. The Cavalier has trained NDA/CDS/SSB aspirants since 2001 (Facebook · YouTube).
Source: Ministry of Health & Family Welfare PIB release, 20 June 2026 (PRID 2275595). Facts cross-verified.